Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Addex Therapeutics ( (CH:ADXN) ) just unveiled an update.
Addex Therapeutics reported that its spin-out Neurosterix has initiated a Phase 1 clinical trial of NTX-253, an orally available positive allosteric modulator of the muscarinic M4 receptor being developed as a novel treatment for schizophrenia. The first-in-human study in healthy volunteers will assess safety, tolerability, pharmacokinetics and pharmacodynamics, marking a significant milestone for both companies and strengthening Addex’s strategic position, as it retains a 20% equity interest in Neurosterix and thus direct exposure to the potential value creation from this differentiated antipsychotic approach, which aims to modulate dopamine signaling while avoiding many side effects associated with traditional dopamine antagonists.
More about Addex Therapeutics
Addex Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders. Its lead candidate, dipraglurant, is being evaluated for future development in brain injury recovery, while partnered and in-house GABAB positive allosteric modulator programs target substance use disorders and chronic cough. Through a 20% equity stake in spin-out Neurosterix and an investment in Swiss biotech Stalicla, Addex is also exposed to emerging precision and allosteric therapies for schizophrenia, psychosis, mood and neurodevelopmental disorders. The company’s shares trade on both the SIX Swiss Exchange and the Nasdaq Capital Market under the ticker “ADXN.”
Average Trading Volume: 209,937
Current Market Cap: CHF7.71M
See more data about ADXN stock on TipRanks’ Stock Analysis page.